Tag: Vaccine

Categories
Health

India Approves Oxford-AstraZeneca Covid-19 Vaccine and 1 Different

India Approves Oxford-AstraZeneca Covid-19 Vaccine and 1 Other

NEW DELHI – India announced on Sunday that it has approved two coronavirus vaccines, one made by AstraZeneca and Oxford University and the other developed in India for emergency use. This is an important step in stopping the coronavirus from spreading in one of the toughest in the world. countries hit.

The permits were announced at a press conference in New Delhi on Sunday. Dr. VG Somani, the Indian drug control officer, said the decision to approve the Oxford-AstraZeneca vaccine and a local vaccine developed by Bharat Biotech was made after “careful review” of both by the Central Drugs Standard Control Organization, India’s Indian medicines agency .

Indian regulators are still considering approvals for other vaccines. One made by Pfizer and BioNTech has already been approved in the US and Europe. Another, Russia’s Sputnik V, seems less far away.

The UK became the first country to issue emergency approval for the Oxford-AstraZeneca vaccine on Wednesday. Argentina soon followed.

Officials in India moved quickly for several reasons. The country ranks number 2 in confirmed infections behind the United States, and the outbreak is widely believed to be worse than official numbers suggest. The pandemic has devastated the economy and the unemployment rate is at a 45-year high. Education has been disrupted, leading to concerns about the long-term impact on the country’s youth.

India is now facing major challenges. Cans for more than 1.3 billion people have to be paid for and distributed over a vast country. Government officials may also have public doubts about the vaccine’s safety and effectiveness, partly due to the government’s lack of transparency about clinical trial protocols.

Criticism of the ambiguity of the data examined by the regulator came quickly after the two emergency vaccines were approved.

All India Drug Action Network, a public health watchdog, immediately issued a statement requesting more information on the scope of clinical trials and dosage regimens for both vaccines.

Regarding the Bharat biotech vaccine called Covaxin, the group said it was “baffled to understand the scientific logic that motivated the top experts” to approve a vaccine that is still in clinical trials.

Dr. Somani, the regulator, said the vaccine had been given to 22,500 study participants and “found safe” to date.

Both the AstraZeneca vaccine and the Bharat Biotech vaccine require two doses, said Dr. Somani. He did not state whether participants in Bharat Biotech’s ongoing clinical trials received both doses.

The effort has already been fraught with setbacks. The Serum Institute, an Indian drug company that had an agreement to make the Oxford vaccine before it was proven to be effective, has managed to produce only about a tenth of the 400 million doses it promised to make before the end of the year.

The government says it’s ready. To get the vaccine to a country known for its size and sometimes unreliable roads, officials will leverage knowledge from nationwide campaigns against polio and newborn vaccinations, as well as the skills and flexibility used in India’s mammoth general election where ballot boxes are delivered to the US furthest from the country.

The Serum Institute says it is on the right track to ramp up production of the vaccine known in India as Covishield. With $ 270 million of its own funds and $ 300 million from the Bill and Melinda Gates Foundation, Serum plans to increase production capacity to 100 million doses per month by February, said Mayank Sen, a company spokesman.

First, the Serum Institute signed a pact with AstraZeneca to manufacture one billion doses of the vaccine for low and middle income countries. The vaccine is attractive to developing countries because it is cheaper to manufacture and easier to transport than those which require colder temperatures during storage and transportation.

The Serum Institute experienced production delays when it built new facilities to manufacture the vaccine. It is said to have produced between 40 and 50 million cans for the world. The company’s chief executive Adar Poonawalla told reporters on Monday that the majority of the cans will be given to India.

Indian officials were unsure of how many doses to receive and when. Mr Sen said the Serum Institute had no firm agreement with the Government of India, but had committed to reserve most of its existing inventory for India.

“The government has not yet signed the papers and the final dotted line, but this is based on initial discussions we had because we have always said India will be the priority,” said Sen.

Until the vaccine is approved by the World Health Organization, serum will begin shipping doses at manufacturing cost to other developing countries, Sen said.

India’s approval process has also been delayed. The Serum Institute filed for emergency approval earlier last month, but regulators requested additional details from clinical trials, including whether any person involved in the trials had had any medical complications.

The details of this claim are not clear. After receiving the Covishield vaccine on October 1, a 40-year-old volunteer from Chennai, India, publicly reported neurological symptoms to the Serum Institute in a legal notice. The company threatened defamation lawsuits and required volunteers to pay approximately $ 13.7 million. While negative health effects from vaccine trials are rare, health professionals risked the Serum Institute promoting misinformation by punishing someone for speaking up.

Mr Poonawalla said Monday that the Serum Institute had submitted the additional information that regulators had requested. It has denied that the problems reported by the Chennai trial participant had anything to do with Covishield but refused to comment on allegations of intimidation.

Indian officials have drawn up an ambitious plan to vaccinate the country’s huge population. This is the greatest effort of this kind in the country’s history.

India plans to launch a vaccination campaign in the first three months of the year that will cover about a quarter of the population by August. The first 30 million people vaccinated will be health care providers, then police and other frontline workers. For the remaining 270 million people, authorities will focus on those over 50 who are suffering from conditions that may make them more vulnerable.

The rest of the population will be immunized based on the availability of vaccines and the latest scientific knowledge.

India has a long history of vaccinating its people. India’s first mass vaccination took place in 1802 to combat smallpox. Subsequent efforts suffered from misinformation and slow adoption.

The country has made progress in recent years. In the fight against polio, government officials ran informational campaigns to religious leaders to almost eradicate the disease. According to a study, a mass measles vaccination campaign between 2010 and 2013 saved the lives of tens of thousands of children.

For the coronavirus campaign, the national government has asked the states to prepare vaccination strategies. Some have established task forces at the state, district and block levels. To date, more than 20,000 health workers in around 260 districts have been trained to administer the vaccine, according to the Indian Ministry of Health.

The government plans to use the framework of its universal vaccination program for pregnant women and newborns – one of the largest and cheapest public health interventions in the world.

Indian civil aviation minister Hardeep Singh Puri said Tuesday that airlines, airports and ground handlers have been asked to develop plans to transport vaccine bottles in cold temperatures.

This week, health workers in four Indian states conducted an exercise to iron out wrinkles. Health officials in various locations distributed over 100 doses of placebo vaccine to trainers. They then tracked the temperature of the cans on the way from the train depot to the vaccination site, as well as the time and whether they reached the intended patient.

India has yet to improve its ability to store and transport vaccines under temperature controlled conditions known as the cold chain network, as well as improve distribution methods and train new workers.

India may need to double its health care workforce from its current 2.5 million, said Thekkekara Jacob John, a senior virologist in southern Tamil Nadu state.

“This is a Herculean task,” said John of the vaccination effort. “And the challenge is not in densely populated cities, but in rural areas – home of real India.”

Government officials must also stop the rumor, he said. Chat groups on WhatsApp, Facebook’s widespread messaging service in India, have already become misinformation about side effects.

A month ago, Prime Minister Narendra Modi urged citizens to look out for those trying to spread rumors about the vaccine, which he called “anti-national and anti-human” and urged politicians to help raise awareness .

Mr Modi renewed that appeal on Thursday, throwing the continued fight against the virus as one against an unknown enemy.

“Be careful of rumors,” he said, “and as a responsible citizen, you must not post messages on social media without checking.”

Categories
Health

42 Individuals in West Virginia Mistakenly Given Virus Remedy As a substitute of Vaccine

42 People in West Virginia Mistakenly Given Virus Treatment Instead of Vaccine

42 people in Boone County, southwest West Virginia, who were due to be given the coronavirus vaccine Wednesday, were instead mistakenly injected with experimental monoclonal antibody treatment, the West Virginia National Guard said Thursday.

None of the 42 recipients have developed any adverse effects to date, the guard said in a statement. The guard who directs the state’s vaccine distribution efforts described the flaw as a “collapse of the process.”

The experimental treatment, a cocktail of antibodies from Regeneron, is the same that President Trump received when he was hospitalized with Covid-19 in November. It is intended to be given as an intravenous infusion, not a direct injection like the vaccine.

Maj. Gen. James Hoyer, the West Virginia National Guard’s adjutant general, said the mix-up appeared to have occurred during the delivery of a shipment of the Regeneron cocktail to a distribution hub where the vials were placed among the supplies of the Moderna vaccine. The hub staff then apparently included the treatment vials in a vaccine shipment to Boone County.

General Hoyer attributed the situation to “a few human errors” and said the guard acted quickly once they realized what had happened. “We have found a problem, we fix it and we are making progress,” he said on Thursday in a radio interview.

No other shipments of the vaccine were affected, the guard said in a statement.

Vials for the treatment and vaccine look somewhat similar but are clearly labeled, as are the boxes they are in. Both are kept refrigerated before use.

The mistake came at a time when record numbers of hospitalizations across the country signaled a greater need than ever for the scarce and expensive antibody treatments, even though some supplies across the country are being kept unused in refrigerators.

Officials in West Virginia reported 1,109 new coronavirus cases and 20 new deaths Thursday. There have been at least 85,334 cases and 1,338 deaths in the state since the pandemic began, according to a database from the New York Times.

Categories
Health

AstraZeneca and Sinopharm clear regulatory hurdles in per week of vaccine milestones.

AstraZeneca and Sinopharm clear regulatory hurdles in a week of vaccine milestones.

With the spread of the coronavirus vaccines developed by Moderna, as well as Pfizer and BioNTech, the world reached several more pandemic milestones this week. the advancement of attempts to examine other experimental recordings; and the approval or approval of coronavirus vaccines in several countries. The welcome news comes as the number of known infections climbs to 83 million worldwide.

  • The UK announced on Wednesday that it was the Oxford-AstraZeneca Vaccine. The vaccine is cheaper than others – $ 3-4 per dose – and unlike some of its freeze-bound counterparts, it can be kept in a regular refrigerator, making it easier to carry and administer. The vaccine should be given in two doses four weeks apart. However, the UK plans to wait up to 12 weeks for the second shot to release more doses for the first injections. Some early evidence suggests the delay might improve the vaccine’s ability to protect people from Covid-19, although experts have repeatedly suggested that more data is needed.

  • The state-owned Chinese company Sinopharm announced that one of its experimental vaccines, developed by the Beijing Institute of Biological Products, had an efficacy rate of 79 percent based on an interim analysis of the Phase 3 trials, prompting the Chinese government to give the shot full approval To give. The vaccine was also approved in the United Arab Emirates and Bahrain. The company has not yet released the detailed results of its late-stage clinical trials.

  • NovavaxThe Maryland-based company announced Monday the start of a late-stage clinical trial that will enroll approximately 30,000 people in the United States and Mexico. Two-thirds of the volunteers in the study will receive the company’s vaccine. The other 10,000 will receive a saline intake as a placebo. Like many other vaccines, Novavax’s vaccine requires two doses. The vaccine can be kept stable in a normal refrigerator.

  • The World Health Organization gave the Pfizer-BioNTech Vaccine Thursday an emergency seal of approval that was the first to be awarded to a Covid-19 vaccine. Adding it to the organization’s emergency list allows the vaccine to move faster through regulatory approval in countries around the world. The move also enables the vaccine to be distributed through Unicef ​​and the Pan American Health Organization.

Categories
Health

A Pharmacist is Arrested After He Allegedly Allowed 500 Vaccine Doses to Spoil

A Pharmacist is Arrested After He Allegedly Allowed 500 Vaccine Doses to Spoil

A pharmacist at a Wisconsin hospital was arrested and charged with deliberately failing to take more than 500 doses of coronavirus vaccine out of the refrigerator last week, the Grafton, Wisconsin Police Department said Thursday.

The hospital administered some of the doses before realizing they were spoiled, the hospital system said.

The pharmacist, a man the police did not name, was arrested on recommended charges of reckless safety endangering, adulteration of a prescription drug and criminal damage to property, all crimes. He is being held in Ozaukee County Jail.

It was not clear what his motive could have been. The Grafton Police Department is investigating the incident with the Federal Bureau of Investigation and the Food and Drug Administration.

The hospital system, Advocate Aurora Health, has evolved since it first found vaccines were taken out of the refrigerator overnight on Dec. 26.

At first it was said that the cans had been accidentally removed. On Wednesday it was said that the pharmacist had admitted to having removed the vials on purpose. On Thursday, Jeff Bahr, the president of Aurora Health Care Medical Group, said in a video call with reporters that the pharmacist admitted taking the vials out of the refrigerator on two consecutive nights – Christmas Eve and Christmas Day – and the hospital did done 57 of the doses given before determining how long they were at room temperature.

Dr. Bahr said there was no evidence that the pharmacist tampered with the vaccine other than taking it out of the refrigerator and that the pharmacist was no longer employed in the hospital system.

Dr. Bahr said the hospital had consulted with Moderna, the pharmaceutical company that made the vaccines, and was reassured that the tainted vaccines would not harm the people who received them. Because the mRNA molecules in the vaccine break apart quickly at room temperature, the doses became “less effective or ineffective,” said Dr. Bahr.

He said the 57 people who received the vaccine had been notified. He did not say what the hospital was up to about further doses for those people who are likely to be healthcare workers, despite Dr. Bahr did not specifically say so.

The hospital didn’t think the incident was due to negligence or gaps in its protocols for managing vaccine doses, said Dr. Bahr.

“It has become clear that this was a situation where a bad actor was involved as opposed to a bad trial,” he said.

Wisconsin saw a devastating surge in coronavirus cases in the fall and was at times the hardest hit state in the country relative to its population. Transmission has slowed down a bit since then, but the state is still reporting 39 new cases per 100,000 people per day. At least 5,195 Wisconsin residents have died.

As of Tuesday, the state had received 156,875 doses of vaccines and administered 47,157 doses, according to the Wisconsin Department of Health.

Categories
Health

Trump officers focus on vaccine rollout as criticism mounts

Trump officials discuss vaccine rollout as criticism mounts

[The stream is slated to start at 12:00 p.m. ET. Please refresh the page if you do not see a player above at that time.]

Department of Health and Human Services and Pentagon officials will hold a joint briefing Wednesday on the Trump administration’s Operation Trump Warp Speed ​​Covid-19 vaccination program.

The briefing comes as the government faces criticism of what appears to be a slower than expected introduction of the vaccines.

As of Monday morning, more than 11.4 million doses of Pfizer and Moderna two-dose vaccines had been distributed across the country, but only about 2.1 million doses were given to people, according to the Centers for Disease Control and Prevention. That’s a far cry from US health officials’ original goal of getting at least 20 million Americans their first shots before the end of the year.

However, the CDC acknowledged delays in their vaccine data from the states and jurisdictions it collects and reports to federal officials, among other things.

“A large difference between the number of doses distributed and the number of doses administered is expected at this point in the COVID vaccination program due to several factors,” the agency said.

President-elect Joe Biden and public health specialists have criticized Trump’s vaccination program in recent days for failing to deliver doses as quickly as they were being distributed.

Read CNBC’s live updates for the latest news on the Covid-19 outbreak.

Categories
Health

Why Coronavirus Vaccine Distribution is Taking Longer Than Anticipated

Here’s Why the ‘Last Mile’ of Vaccine Distribution Is Going So Slowly

In Florida, less than one-quarter of delivered coronavirus vaccines have been used, even as older people sat in lawn chairs all night waiting for their shots. In Puerto Rico, last week’s vaccine shipments did not arrive until the workers who would have administered them had left for the Christmas holiday. In California, doctors are worried about whether there will be enough hospital staff members to both administer vaccines and tend to the swelling number of Covid-19 patients.

These sorts of logistical problems in clinics across the country have put the campaign to vaccinate the United States against Covid-19 far behind schedule in its third week, raising fears about how quickly the country will be able to tame the epidemic.

Federal officials said as recently as this month that their goal was to have 20 million people get their first shot by the end of this year. More than 14 million doses of the Pfizer and Moderna vaccines had been sent out across the United States, federal officials said on Wednesday. But, according to the Centers for Disease Control and Prevention, just 2.8 million people have received their first dose, though that number may be somewhat low because of lags in reporting.

States vary widely in how many of the doses they’ve received have been given out. South Dakota leads the country with more than 48 percent of its doses given, followed by West Virginia, at 38 percent. By contrast, Kansas has given out less than 11 percent of its doses, and Georgia, less than 14 percent.

Compounding the challenges, federal officials say they do not fully understand the cause of the delays. But state health officials and hospital leaders throughout the country pointed to several factors. States have held back doses to be given out to their nursing homes and other long-term-care facilities, an effort that is just gearing up and expected to take several months. Across the country, just 8 percent of the doses distributed for use in these facilities have been administered, with two million yet to be given.

The holiday season has meant that people are off work and clinics have reduced hours, slowing the pace of vaccine administration. In Florida, for example, the demand for the vaccines dipped over the Christmas holiday and is expected to dip again over New Year’s, Gov. Ron DeSantis said on Wednesday.

And critically, public health experts say, federal officials have left many of the details of the final stage of the vaccine distribution process, such as scheduling and staffing, to overstretched local health officials and hospitals.

In one notable blunder, forty-two people in Boone County, W.Va., who were scheduled to receive the coronavirus vaccine on Wednesday instead were mistakenly injected with an experimental monoclonal antibody treatment.

The West Virginia National Guard, which is leading the state’s vaccine distribution effort, called the error “a breakdown in the process.” None of the recipients has developed any adverse effects so far.

“We’ve taken the people with the least amount of resources and capacity and asked them to do the hardest part of the vaccination — which is actually getting the vaccines administered into people’s arms,” said Dr. Ashish Jha, the dean of Brown University’s School of Public Health.

Federal and state officials have denied they are to blame for the slow rollout. Officials behind Operation Warp Speed, the federal effort to fast-track vaccines, have said that their job was to ensure that vaccines are made available and get shipped out to the states. President Trump said in a tweet on Tuesday that it was “up to the States to distribute the vaccines once brought to the designated areas by the Federal Government.”

“Ultimately, the buck seems to stop with no one,” Dr. Jha said.

These problems are especially worrisome now that a new, more contagious variant, first spotted in Britain and overwhelming hospitals there, has arrived in the U.S. Officials in two states, Colorado and California, say they have discovered cases of the new variant, and none of the patients had recently traveled, suggesting the variant is already spreading in American communities.

The $900 billion relief package that Mr. Trump signed into law on Sunday will bring some relief to struggling state and local health departments. The bill sets aside more than $8 billion for vaccine distribution, on top of the $340 million that the C.D.C. sent out to the states in installments in September and earlier this month.

That infusion of money is welcome, if late, said Dr. Bob Wachter, a professor and chair of the department of medicine at the University of California, San Francisco. “Why did that take until now when we knew we were going to have this problem two months ago?”

Michael Pratt, a spokesman for Operation Warp Speed, said that there will always be lags between the number of doses that have been allocated, shipped, injected and reported. “We’re working to make those lags as small as possible,” Mr. Pratt said.

Covid-19 Vaccines ›

Answers to Your Vaccine Questions

With distribution of a coronavirus vaccine beginning in the U.S., here are answers to some questions you may be wondering about:

    • If I live in the U.S., when can I get the vaccine? While the exact order of vaccine recipients may vary by state, most will likely put medical workers and residents of long-term care facilities first. If you want to understand how this decision is getting made, this article will help.
    • When can I return to normal life after being vaccinated? Life will return to normal only when society as a whole gains enough protection against the coronavirus. Once countries authorize a vaccine, they’ll only be able to vaccinate a few percent of their citizens at most in the first couple months. The unvaccinated majority will still remain vulnerable to getting infected. A growing number of coronavirus vaccines are showing robust protection against becoming sick. But it’s also possible for people to spread the virus without even knowing they’re infected because they experience only mild symptoms or none at all. Scientists don’t yet know if the vaccines also block the transmission of the coronavirus. So for the time being, even vaccinated people will need to wear masks, avoid indoor crowds, and so on. Once enough people get vaccinated, it will become very difficult for the coronavirus to find vulnerable people to infect. Depending on how quickly we as a society achieve that goal, life might start approaching something like normal by the fall 2021.
    • If I’ve been vaccinated, do I still need to wear a mask? Yes, but not forever. Here’s why. The coronavirus vaccines are injected deep into the muscles and stimulate the immune system to produce antibodies. This appears to be enough protection to keep the vaccinated person from getting ill. But what’s not clear is whether it’s possible for the virus to bloom in the nose — and be sneezed or breathed out to infect others — even as antibodies elsewhere in the body have mobilized to prevent the vaccinated person from getting sick. The vaccine clinical trials were designed to determine whether vaccinated people are protected from illness — not to find out whether they could still spread the coronavirus. Based on studies of flu vaccine and even patients infected with Covid-19, researchers have reason to be hopeful that vaccinated people won’t spread the virus, but more research is needed. In the meantime, everyone — even vaccinated people — will need to think of themselves as possible silent spreaders and keep wearing a mask. Read more here.
    • Will it hurt? What are the side effects? The Pfizer and BioNTech vaccine is delivered as a shot in the arm, like other typical vaccines. The injection into your arm won’t feel different than any other vaccine, but the rate of short-lived side effects does appear higher than a flu shot. Tens of thousands of people have already received the vaccines, and none of them have reported any serious health problems. The side effects, which can resemble the symptoms of Covid-19, last about a day and appear more likely after the second dose. Early reports from vaccine trials suggest some people might need to take a day off from work because they feel lousy after receiving the second dose. In the Pfizer study, about half developed fatigue. Other side effects occurred in at least 25 to 33 percent of patients, sometimes more, including headaches, chills and muscle pain. While these experiences aren’t pleasant, they are a good sign that your own immune system is mounting a potent response to the vaccine that will provide long-lasting immunity.
    • Will mRNA vaccines change my genes? No. The vaccines from Moderna and Pfizer use a genetic molecule to prime the immune system. That molecule, known as mRNA, is eventually destroyed by the body. The mRNA is packaged in an oily bubble that can fuse to a cell, allowing the molecule to slip in. The cell uses the mRNA to make proteins from the coronavirus, which can stimulate the immune system. At any moment, each of our cells may contain hundreds of thousands of mRNA molecules, which they produce in order to make proteins of their own. Once those proteins are made, our cells then shred the mRNA with special enzymes. The mRNA molecules our cells make can only survive a matter of minutes. The mRNA in vaccines is engineered to withstand the cell’s enzymes a bit longer, so that the cells can make extra virus proteins and prompt a stronger immune response. But the mRNA can only last for a few days at most before they are destroyed.

The task of administering thousands of vaccines is daunting for health departments that have already been overburdened by responding to the pandemic. In Montgomery County, Maryland, the local health department has recruited extra staff to help manage vaccine distribution, said Travis Gayles, the county health officer.

“While we’re trying to roll out vaccinations, we’re also continuing the pandemic response by supporting testing, contact tracing, disease control and all of those other aspects of the Covid response,” Dr. Gayles said.

Complicating matters, the county health department gets just a few days of notice each week of the timing of its vaccine shipments. When the latest batch arrived, Dr. Gayles’s team scrambled to contact people eligible for the vaccine and to set up clinics to give out the doses as fast as possible.

Over all, Maryland has given nearly 17 percent of its vaccine doses. In a Wednesday appearance on CBS, Gov. Larry Hogan attributed the slow process to challenges across the board — from the federal government not sending as many doses as initially predicted, to the lack of logistical and financial support for local health departments.

In Texas, Gov. Greg Abbott and top state health officials say vaccines are available in the state but are not being distributed quickly enough to deal with a critical surge of Covid-19 cases that is pushing hospital capacity to the breaking point.

“A significant portion of vaccines distributed across Texas might be sitting on hospital shelves as opposed to being given to vulnerable Texans,” the governor tweeted Tuesday.

In California, Gov. Gavin Newsom on Wednesday encouraged people to be “humble” in the face of such a complicated task and said that the pace of vaccination would accelerate. California has administered 20 percent of the doses it’s received.

Hesitancy among people offered the vaccine may also be slowing the rollout. Gov. Mike DeWine of Ohio said in a news conference on Wednesday that roughly 60 percent of nursing home staff members offered the vaccine in the state had declined it. In Florida, some hospital workers offered the vaccine declined it, and those doses are now designated for other vulnerable groups like health care workers in the community and the elderly, but that rollout has not quite begun, said Justin Senior, chief executive officer for the Safety Net Hospital Alliance of Florida, a hospital consortium.

There are bright spots. Some states and hospitals are finding ways to speedily administer the vaccines they have received. West Virginia said on Wednesday that it had finished giving the first round of vaccine doses to willing residents and workers at all of the state’s 214 long-term-care facilities — putting the state far ahead of most other states that began vaccinating at these facilities under a federal program with CVS and Walgreens.

In Los Angeles, Cedars-Sinai Medical Center, which employs some 20,000 people at several facilities, was vaccinating about 800 people a day, said Dr. Jeff Smith, Cedars-Sinai’s chief operating officer. He said Cedars-Sinai expected to vaccinate all of its staff members who have opted for the vaccine within a couple of weeks.

But other communities are falling short of that rapid clip. Dr. Smith said the medical community is worried about staffing shortages when hospitals have to both administer vaccines and treat Covid-19 patients.

In a news conference on Wednesday, Operation Warp Speed officials said they expected the pace of the rollout to accelerate significantly once pharmacies begin offering vaccines in their stores. The federal government has reached agreements with a number of pharmacy chains — including Costco, Walmart, and CVS — to administer vaccines once they become more widely available. So far, 40,000 pharmacy locations have enrolled in that program.

Most vaccines administered across the country to date have been given to health care workers at hospitals and clinics, and to older adults at nursing homes. Gen. Gustave F. Perna, the logistics lead of Operation Warp Speed, on Wednesday described them as “two very difficult, challenging groups” to immunize.

But public health officials warned that reaching these initial groups, who are largely being vaccinated where they live or work, is a relatively easy task. “This is the part where we’re supposed to know where people are,” said Dr. Saad B. Omer, the director of the Yale Institute for Global Health.

It may be more difficult, public health officials say, to vaccinate the next wave of people, which will most likely include many more older Americans as well as younger people with health problems and frontline workers. Among the fresh challenges: How will these people be scheduled for their vaccination appointments? How will they provide documentation that they have a medical condition or a job that makes them eligible to get vaccinated? And how will pharmacies ensure that people show up, and that they can do so safely?

“In the next phase,” said Dr. Jha of Brown University, “we’re going to hit the same wall, where all of a sudden we’re going to have to scramble to start figuring it out.”

Lucy Tompkins and David Montgomery contributed reporting.

Categories
Health

West Virginia mistakenly provides 42 individuals Regeneron IV Covid therapy as a substitute of vaccine shot

West Virginia mistakenly gives 42 people Regeneron IV Covid treatment instead of vaccine shot

A pharmacist dilutes the Pfizer COVID-19 vaccine as he prepares it for administration to staff and residents at Goodwin House Bailey’s Crossroads, a senior community in Falls Church, Virginia, on December 30, 2020.

Brendan Smialowski | AFP | Getty Images

Dozens of people in West Virginia were mistakenly given Regeneron’s Covid-19 antibodies instead of the Moderna vaccine, the West Virginia National Guard said Thursday.

According to the state’s National Guard, 42 people received the intravenous treatment at a Boone County Department of Health vaccination clinic. The National Guard said it learned of the mistake on Wednesday.

Everyone who received the antibody treatment instead of the vaccine, which is given through a shot in the arm, has been contacted, Julie Miller, a Boone County Health Department administrator, told CNBC via email. She added, “We don’t think there is any risk of harm.”

Regeneron’s monoclonal antibody treatment, which must be given via an IV drip, is seen as a promising treatment for Covid-19 – especially if given early in the course of the infection. But the West Virginia mix-up is just one example of the confusion in the rush to distribute the vaccine to tens of millions of people. The rollout was slower than expected and was characterized by logistical challenges.

“It was determined that this was an isolated incident,” Miller said. “All those affected will be offered the COVID-19 vaccine today.”

She said the health department will work closely with the state National Guard and the Department of Health and Human Resources to review their policies and procedures.

Miller did not provide details on what caused the mix-up.

Representatives from the West Virginia National Guard and the West Virginia Governor’s Office did not respond to CNBC’s request for further comment on the occurrence of the error.

Maj. Gen. James Hoyer, adjutant general of the West Virginia National Guard, said in a statement that his forces “acted immediately” to correct the mistake as soon as they found out what happened. “We immediately reviewed and strengthened our logs to improve our sales process and prevent this from happening again,” he said in a statement.

He added that the state will continue to promote the vaccine “to save more lives every day”.

Dr. Clay Marsh, the state’s Covid-19 tsar, noted in a statement that the Regeneron treatment mistakenly given in place of the vaccine is the same product “that was given to President Trump when he became infected”.

“Although this injection is not harmful, it has replaced the vaccine,” he said. “However, this event provides an important opportunity for our leadership team to review and improve the safety and vaccination process for every West Virginian.”

Categories
Business

Dr. Fauci says gradual Covid vaccine rollout has been ‘disappointing’

Fauci warns of post-Christmas surge in Covid infections

Anthony Fauci, director of the National Institute for Allergies and Infectious Diseases, speaks to Alex Azar, the unpictured Secretary for Health and Human Services (HHS), before receiving the Cova-19 vaccine from Moderna Inc. during an event at the NIH Clinical that Center Masur Auditorium in Bethesda, Maryland, the United States, on Tuesday, December 22, 2020. The National Institutes of Health are hosting a livestream vaccination event to kickstart the organization’s efforts for its workers on the front lines of the pandemic. Photographer: Patrick Semansky / Associated Press / Bloomberg via Getty Images

Bloomberg | Bloomberg | Getty Images

According to Dr. Anthony Fauci, director of the National Institute of Allergies and Infectious Diseases, was disappointing with the slower-than-expected adoption of Covid vaccines in the US.

Officials from Operation Warp Speed, President Donald Trump’s vaccination program, said the country would immunize 20 million people with the first of the two Covid-19 vaccines in December. According to the Centers for Disease Control and Prevention, of more than 12.4 million doses distributed, nearly 2.8 million were actually administered.

“We would have liked to see it go smoothly and have 20 million doses administered to people by the end of 2020 (year). That was the projection. Obviously it didn’t and that’s disappointing,” Fauci said Thursday on NBCs ” TODAY “show. “Hopefully the increasing momentum in the first few weeks of January will get us to where we want to be.”

States and counties need more resources to speed up the pace of vaccination, Fauci said. Trump has been defending his administration’s rollout for the past few days, saying it is the responsibility of states to manage the shots as soon as they are delivered by Operation Warp Speed.

Michael Pratt, a spokesperson for the program, said earlier this week that the CDC’s data is likely to be incorrect due to delays in reporting.

“Operation Warp Speed ​​remains on track to deliver approximately 40 million vaccine doses and 20 million primary vaccination doses by the end of December 2020. The distribution of the 20 million primary doses extends into the first week of January when states place orders she, “he said in a statement.

Dr. Paul Offit, director of the Vaccine Education Center at Pennsylvania Children’s Hospital, told CNN Thursday that the federal government had invested heavily in vaccine development, but had failed to meet those efforts in terms of distribution and administration.

“With the urgency we put into making a vaccine and the money we put into making a vaccine, we spent $ 24 billion on what was essentially a Manhattan Project-style response. .. That’s the vaccine part, “he said. “Now comes the vaccination part that is just as difficult and will equally require this Manhattan Project-like response.”

“The federal government needs to step up its response to vaccination in the same way that it stepped up its response to making the vaccine,” said Offit, a voting member of the Food and Drug Administration’s Advisory Committee on Vaccines and Related Biological Products.

Dr. Jonathan Reiner, professor of medicine and surgery at the George Washington University School of Medicine and Health, calls for “mass vaccination” events. He said the government should consider converting places like polling stations, soccer stadiums and race tracks into temporary vaccination clinics.

“We have to vaccinate about 2 million people a day … versus 150,000 people a day. And I just don’t see the urgency,” he told CNN on Thursday.

Also on Thursday, New York City Mayor Bill de Blasio said the city would use schools, pop-up clinics and “whatever it takes” to deliver 1 million vaccinations by the end of January. “We have to switch to mass vaccination mode and we have to do that now.”

Categories
Health

Right here’s Why the ‘Final Mile’ of Vaccine Distribution Is Going So Slowly

Here’s Why the ‘Last Mile’ of Vaccine Distribution Is Going So Slowly

In Florida, less than one-quarter of delivered coronavirus vaccines have been used, even as older people sat in lawn chairs all night waiting for their shots. In Puerto Rico, last week’s vaccine shipments did not arrive until the workers who would have administered them had left for the Christmas holiday. In California, doctors are worried about whether there will be enough hospital staff members to both administer vaccines and tend to the swelling number of Covid-19 patients.

These sorts of logistical problems in clinics across the country have put the campaign to vaccinate the United States against Covid-19 far behind schedule in its third week, raising fears about how quickly the country will be able to tame the epidemic.

Federal officials said as recently as this month that their goal was to have 20 million people get their first shot by the end of this year. More than 14 million doses of the Pfizer and Moderna vaccines had been sent out across the United States, federal officials said on Wednesday. But, according to the Centers for Disease Control and Prevention, just 2.8 million people have received their first dose, though that number may be somewhat low because of lags in reporting.

States vary widely in how many of the doses they’ve received have been given out. South Dakota leads the country with more than 48 percent of its doses given, followed by West Virginia, at 38 percent. By contrast, Kansas has given out less than 11 percent of its doses, and Georgia, less than 14 percent.

Compounding the challenges, federal officials say they do not fully understand the cause of the delays. But state health officials and hospital leaders throughout the country pointed to several factors. States have held back doses to be given out to their nursing homes and other long-term-care facilities, an effort that is just gearing up and expected to take several months. Across the country, just 8 percent of the doses distributed for use in these facilities have been administered, with two million yet to be given.

The holiday season has meant that people are off work and clinics have reduced hours, slowing the pace of vaccine administration. In Florida, for example, the demand for the vaccines dipped over the Christmas holiday and is expected to dip again over New Year’s, Gov. Ron DeSantis said on Wednesday.

And critically, public health experts say, federal officials have left many of the details of the final stage of the vaccine distribution process, such as scheduling and staffing, to overstretched local health officials and hospitals.

“We’ve taken the people with the least amount of resources and capacity and asked them to do the hardest part of the vaccination — which is actually getting the vaccines administered into people’s arms,” said Dr. Ashish Jha, the dean of Brown University’s School of Public Health.

Federal and state officials have denied they are to blame for the slow rollout. Officials behind Operation Warp Speed, the federal effort to fast-track vaccines, have said that their job was to ensure that vaccines are made available and get shipped out to the states. President Trump said in a tweet on Tuesday that it was “up to the States to distribute the vaccines once brought to the designated areas by the Federal Government.”

“Ultimately, the buck seems to stop with no one,” Dr. Jha said.

These problems are especially worrisome now that a new, more contagious variant, first spotted in Britain and overwhelming hospitals there, has arrived in the U.S. Officials in two states, Colorado and California, say they have discovered cases of the new variant, and none of the patients had recently traveled, suggesting the variant is already spreading in American communities.

The $900 billion relief package that Mr. Trump signed into law on Sunday will bring some relief to struggling state and local health departments. The bill sets aside more than $8 billion for vaccine distribution, on top of the $340 million that the C.D.C. sent out to the states in installments in September and earlier this month.

That infusion of money is welcome, if late, said Dr. Bob Wachter, a professor and chair of the department of medicine at the University of California, San Francisco. “Why did that take until now when we knew we were going to have this problem two months ago?”

Covid-19 Vaccines ›

Answers to Your Vaccine Questions

With distribution of a coronavirus vaccine beginning in the U.S., here are answers to some questions you may be wondering about:

    • If I live in the U.S., when can I get the vaccine? While the exact order of vaccine recipients may vary by state, most will likely put medical workers and residents of long-term care facilities first. If you want to understand how this decision is getting made, this article will help.
    • When can I return to normal life after being vaccinated? Life will return to normal only when society as a whole gains enough protection against the coronavirus. Once countries authorize a vaccine, they’ll only be able to vaccinate a few percent of their citizens at most in the first couple months. The unvaccinated majority will still remain vulnerable to getting infected. A growing number of coronavirus vaccines are showing robust protection against becoming sick. But it’s also possible for people to spread the virus without even knowing they’re infected because they experience only mild symptoms or none at all. Scientists don’t yet know if the vaccines also block the transmission of the coronavirus. So for the time being, even vaccinated people will need to wear masks, avoid indoor crowds, and so on. Once enough people get vaccinated, it will become very difficult for the coronavirus to find vulnerable people to infect. Depending on how quickly we as a society achieve that goal, life might start approaching something like normal by the fall 2021.
    • If I’ve been vaccinated, do I still need to wear a mask? Yes, but not forever. Here’s why. The coronavirus vaccines are injected deep into the muscles and stimulate the immune system to produce antibodies. This appears to be enough protection to keep the vaccinated person from getting ill. But what’s not clear is whether it’s possible for the virus to bloom in the nose — and be sneezed or breathed out to infect others — even as antibodies elsewhere in the body have mobilized to prevent the vaccinated person from getting sick. The vaccine clinical trials were designed to determine whether vaccinated people are protected from illness — not to find out whether they could still spread the coronavirus. Based on studies of flu vaccine and even patients infected with Covid-19, researchers have reason to be hopeful that vaccinated people won’t spread the virus, but more research is needed. In the meantime, everyone — even vaccinated people — will need to think of themselves as possible silent spreaders and keep wearing a mask. Read more here.
    • Will it hurt? What are the side effects? The Pfizer and BioNTech vaccine is delivered as a shot in the arm, like other typical vaccines. The injection into your arm won’t feel different than any other vaccine, but the rate of short-lived side effects does appear higher than a flu shot. Tens of thousands of people have already received the vaccines, and none of them have reported any serious health problems. The side effects, which can resemble the symptoms of Covid-19, last about a day and appear more likely after the second dose. Early reports from vaccine trials suggest some people might need to take a day off from work because they feel lousy after receiving the second dose. In the Pfizer study, about half developed fatigue. Other side effects occurred in at least 25 to 33 percent of patients, sometimes more, including headaches, chills and muscle pain. While these experiences aren’t pleasant, they are a good sign that your own immune system is mounting a potent response to the vaccine that will provide long-lasting immunity.
    • Will mRNA vaccines change my genes? No. The vaccines from Moderna and Pfizer use a genetic molecule to prime the immune system. That molecule, known as mRNA, is eventually destroyed by the body. The mRNA is packaged in an oily bubble that can fuse to a cell, allowing the molecule to slip in. The cell uses the mRNA to make proteins from the coronavirus, which can stimulate the immune system. At any moment, each of our cells may contain hundreds of thousands of mRNA molecules, which they produce in order to make proteins of their own. Once those proteins are made, our cells then shred the mRNA with special enzymes. The mRNA molecules our cells make can only survive a matter of minutes. The mRNA in vaccines is engineered to withstand the cell’s enzymes a bit longer, so that the cells can make extra virus proteins and prompt a stronger immune response. But the mRNA can only last for a few days at most before they are destroyed.

The task of administering thousands of vaccines is daunting for health departments that have already been overburdened by responding to the pandemic. In Montgomery County, Maryland, the local health department has recruited extra staff to help manage vaccine distribution, said Travis Gayles, the county health officer.

“While we’re trying to roll out vaccinations, we’re also continuing the pandemic response by supporting testing, contact tracing, disease control and all of those other aspects of the Covid response,” Dr. Gayles said.

Complicating matters, the county health department gets just a few days of notice each week of the timing of its vaccine shipments. When the latest batch arrived, Dr. Gayles’s team scrambled to contact people eligible for the vaccine and to set up clinics to give out the doses as fast as possible.

Over all, Maryland has given nearly 17 percent of its vaccine doses. In a Wednesday appearance on CBS, Gov. Larry Hogan attributed the slow process to challenges across the board — from the federal government not sending as many doses as initially predicted, to the lack of logistical and financial support for local health departments.

In Texas, Gov. Greg Abbott and top state health officials say vaccines are available in the state but are not being distributed quickly enough to deal with a critical surge of Covid-19 cases that is pushing hospital capacity to the breaking point.

“A significant portion of vaccines distributed across Texas might be sitting on hospital shelves as opposed to being given to vulnerable Texans,” the governor tweeted Tuesday.

In California, Gov. Gavin Newsom on Wednesday encouraged people to be “humble” in the face of such a complicated task and said that the pace of vaccination would accelerate. California has administered 20 percent of the doses it’s received.

Hesitancy among people offered the vaccine may also be slowing the rollout. Gov. Mike DeWine of Ohio said in a news conference on Wednesday that roughly 60 percent of nursing home staff members offered the vaccine in the state had declined it. In Florida, some hospital workers offered the vaccine declined it, and those doses are now designated for other vulnerable groups like health care workers in the community and the elderly, but that rollout has not quite begun, said Justin Senior, chief executive officer for the Safety Net Hospital Alliance of Florida, a hospital consortium.

There are bright spots. Some states and hospitals are finding ways to speedily administer the vaccines they have received. West Virginia said on Wednesday that it had finished giving the first round of vaccine doses to willing residents and workers at all of the state’s 214 long-term-care facilities — putting the state far ahead of most other states that began vaccinating at these facilities under a federal program with CVS and Walgreens.

In Los Angeles, Cedars-Sinai Medical Center, which employs some 20,000 people at several facilities, was vaccinating about 800 people a day, said Dr. Jeff Smith, Cedars-Sinai’s chief operating officer. He said Cedars-Sinai expected to vaccinate all of its staff members who have opted for the vaccine within a couple of weeks.

But other communities are falling short of that rapid clip. Dr. Smith said the medical community is worried about staffing shortages when hospitals have to both administer vaccines and treat Covid-19 patients.

In a news conference on Wednesday, Operation Warp Speed officials said they expected the pace of the rollout to accelerate significantly once pharmacies begin offering vaccines in their stores. The federal government has reached agreements with a number of pharmacy chains — including Costco, Walmart, and CVS — to administer vaccines once they become more widely available. So far, 40,000 pharmacy locations have enrolled in that program.

Most vaccines administered across the country to date have been given to health care workers at hospitals and clinics, and to older adults at nursing homes. Gen. Gustave F. Perna, the logistics lead of Operation Warp Speed, on Wednesday described them as “two very difficult, challenging groups” to immunize.

But public health officials warned that reaching these initial groups, who are largely being vaccinated where they live or work, is a relatively easy task. “This is the part where we’re supposed to know where people are,” said Dr. Saad B. Omer, the director of the Yale Institute for Global Health.

It may be more difficult, public health officials say, to vaccinate the next wave of people, which will most likely include many more older Americans as well as younger people with health problems and frontline workers. Among the fresh challenges: How will these people be scheduled for their vaccination appointments? How will they provide documentation that they have a medical condition or a job that makes them eligible to get vaccinated? And how will pharmacies ensure that people show up, and that they can do so safely?

“In the next phase,” said Dr. Jha of Brown University, “we’re going to hit the same wall, where all of a sudden we’re going to have to scramble to start figuring it out.”

Lucy Tompkins and David Montgomery contributed reporting.

Categories
Business

China Approves Sinopharm’s Covid-19 Vaccine because it Strikes to Inoculate Tens of millions

China Approves Sinopharm's Covid-19 Vaccine as it Moves to Inoculate Millions

The Chinese government said on Thursday that it had approved a homegrown coronavirus vaccine after an early analysis of clinical trial results showed that it was effective. The announcements sent a positive signal for the global rollout of Chinese vaccines but lacked crucial details.

The manufacturer, a state-controlled firm called Sinopharm, said on Wednesday that a vaccine candidate made by its Beijing Institute of Biological Products arm had an efficacy rate of 79 percent based on an interim analysis of Phase 3 trials. Sinopharm said it had filed an application with Chinese regulators to allow the vaccine to be used broadly, and on Thursday the government said the vaccine had been granted conditional approval.

If supported, the interim results will bolster claims that Chinese officials have made in recent days that the country’s vaccines are safe and effective. Even before the government issued its official approval, the authorities had already moved ahead with mass vaccinations, defying industry norms. They plan to vaccinate 50 million people in China by mid-February, when hundreds of millions are expected to travel for the Lunar New Year holiday.

But Sinopharm’s announcement provided no breakdown of results and left many questions unanswered, adding to a lack of clarity that has dogged China’s coronavirus vaccine development for months. Wu Yonglin, Sinopharm’s president, said on Thursday that the company would publish details of the trials in major academic journals later.

China’s drive to develop a homegrown vaccine speaks to the country’s technological and diplomatic ambitions. A successful vaccine would support the country’s claim as a peer and rival to the United States and other developed countries in biomedical sciences.

The Sinopharm vaccine’s results show that it is less effective than others that have been approved in other countries. Still, the results are well above the 50 percent threshold that makes a vaccine effective in the eyes of the medical establishment.

Two other coronavirus vaccines, made by Moderna and Pfizer-BioNTech, have been shown to have an efficacy rate of about 95 percent. The Pfizer-BioNTech vaccine has received authorization in more than 40 countries. Moderna’s vaccine has been authorized in the United States, and other countries are evaluating its trial results. Russia has announced that its Sputnik V vaccine has an efficacy rate of 91 percent and has begun a mass vaccination campaign.

Beijing has leaned heavily on the promise of its vaccines to strengthen ties with developing countries deemed vital to China’s interests. Officials have toured the world pledging to provide Chinese vaccines as a “global public good,” a charm offensive that the United States may seek to counter, particularly when the campaign encroaches on its backyard.

The political stakes in the race for a vaccine are particularly high for China’s authoritarian Communist Party, which has been criticized for stifling information and playing down the virus when it first emerged in the city of Wuhan late last year.

A successful vaccine, if quickly made available to the world, could help repair the party’s image globally and that of its leader, Xi Jinping. The Chinese companies have said their vaccine would be cheaper and easier to transport, which if proven could give them significant appeal in the developing world.

Chinese vaccines may still be greeted with other questions. Scientists said that the headline figures released by Sinopharm were encouraging but that the lack of supporting data made it difficult for the results to be independently assessed.

Covid-19 Vaccines ›

Answers to Your Vaccine Questions

With distribution of a coronavirus vaccine beginning in the U.S., here are answers to some questions you may be wondering about:

    • If I live in the U.S., when can I get the vaccine? While the exact order of vaccine recipients may vary by state, most will likely put medical workers and residents of long-term care facilities first. If you want to understand how this decision is getting made, this article will help.
    • When can I return to normal life after being vaccinated? Life will return to normal only when society as a whole gains enough protection against the coronavirus. Once countries authorize a vaccine, they’ll only be able to vaccinate a few percent of their citizens at most in the first couple months. The unvaccinated majority will still remain vulnerable to getting infected. A growing number of coronavirus vaccines are showing robust protection against becoming sick. But it’s also possible for people to spread the virus without even knowing they’re infected because they experience only mild symptoms or none at all. Scientists don’t yet know if the vaccines also block the transmission of the coronavirus. So for the time being, even vaccinated people will need to wear masks, avoid indoor crowds, and so on. Once enough people get vaccinated, it will become very difficult for the coronavirus to find vulnerable people to infect. Depending on how quickly we as a society achieve that goal, life might start approaching something like normal by the fall 2021.
    • If I’ve been vaccinated, do I still need to wear a mask? Yes, but not forever. Here’s why. The coronavirus vaccines are injected deep into the muscles and stimulate the immune system to produce antibodies. This appears to be enough protection to keep the vaccinated person from getting ill. But what’s not clear is whether it’s possible for the virus to bloom in the nose — and be sneezed or breathed out to infect others — even as antibodies elsewhere in the body have mobilized to prevent the vaccinated person from getting sick. The vaccine clinical trials were designed to determine whether vaccinated people are protected from illness — not to find out whether they could still spread the coronavirus. Based on studies of flu vaccine and even patients infected with Covid-19, researchers have reason to be hopeful that vaccinated people won’t spread the virus, but more research is needed. In the meantime, everyone — even vaccinated people — will need to think of themselves as possible silent spreaders and keep wearing a mask. Read more here.
    • Will it hurt? What are the side effects? The Pfizer and BioNTech vaccine is delivered as a shot in the arm, like other typical vaccines. The injection into your arm won’t feel different than any other vaccine, but the rate of short-lived side effects does appear higher than a flu shot. Tens of thousands of people have already received the vaccines, and none of them have reported any serious health problems. The side effects, which can resemble the symptoms of Covid-19, last about a day and appear more likely after the second dose. Early reports from vaccine trials suggest some people might need to take a day off from work because they feel lousy after receiving the second dose. In the Pfizer study, about half developed fatigue. Other side effects occurred in at least 25 to 33 percent of patients, sometimes more, including headaches, chills and muscle pain. While these experiences aren’t pleasant, they are a good sign that your own immune system is mounting a potent response to the vaccine that will provide long-lasting immunity.
    • Will mRNA vaccines change my genes? No. The vaccines from Moderna and Pfizer use a genetic molecule to prime the immune system. That molecule, known as mRNA, is eventually destroyed by the body. The mRNA is packaged in an oily bubble that can fuse to a cell, allowing the molecule to slip in. The cell uses the mRNA to make proteins from the coronavirus, which can stimulate the immune system. At any moment, each of our cells may contain hundreds of thousands of mRNA molecules, which they produce in order to make proteins of their own. Once those proteins are made, our cells then shred the mRNA with special enzymes. The mRNA molecules our cells make can only survive a matter of minutes. The mRNA in vaccines is engineered to withstand the cell’s enzymes a bit longer, so that the cells can make extra virus proteins and prompt a stronger immune response. But the mRNA can only last for a few days at most before they are destroyed.

Sinopharm on Wednesday did not disclose the size of the trial population or provide detailed information about any serious side effects, data points that scientists look for in such releases. On Thursday, Mr. Wu, Sinopharm’s president, said at a news briefing that more than 60,000 people had been vaccinated as part of the trials.

“With each of these vaccines we’re dealing with bits and pieces of information, but the Chinese companies have provided even less information than the Russian companies have,” said Dr. Kim Mulholland, a pediatrician at the Murdoch Children’s Research Institute in Melbourne, Australia.

“At least with the Russian vaccines we were told the number of cases and the basis of evidence for why their vaccine was effective,” said Dr. Mulholland, who has been involved in the oversight of many vaccine trials, including ones for a Covid-19 vaccine.

Michael Baker, a professor with the department of global health at the University of Otago in Wellington who is an adviser to the New Zealand government, said that while the initial figures from Sinopharm looked promising, without more information it was difficult to know for sure.

“It’s pretty light on the details,” he said. “One question is: What markets do they propose to use these vaccines in? Because if they want to have a global market, they’re obviously going to have to supply all those details.”

Details about the efficacy of another Chinese vaccine candidate, made by Sinovac, a private Beijing-based vaccine maker, have also been released in a piecemeal fashion.

The absence of detailed information on the safety and efficacy of Chinese vaccines has not stopped officials in the country from administering them to the public. Officials in several provinces and cities say they are focusing on what China calls “key priority groups” — doctors, hotel employees, border inspection personnel and workers in food storage and transportation, as well as travelers — in an ongoing inoculation drive.

Chinese officials and companies had already administered Chinese-made vaccines, mostly made by Sinopharm, to more than a million people in China. The campaign drew criticism from overseas scientists who said they were concerned that the authorities did not closely monitor people after they received injections outside clinical trials.

To China, a vaccine that can help protect its 1.4 billion people is crucial to its plans to revitalize the economy.

The country has largely stamped out the coronavirus with a combination of restrictions on foreign arrivals, mass testing and tight lockdowns of neighborhoods whenever any cases are detected. But officials remain concerned that the winter could bring a new wave of infections and hope that a widely available vaccine can help prepare the country for when regular travel and trade resume.

Already, new local outbreaks were being reported in Beijing and the northern city of Shenyang this week, prompting the imposition of new measures. In Shenyang, officials declared that the city was in “wartime status” as they rolled out restrictions on large-scale gatherings including group meals, training sessions and end-of-year parties.

Sinovac and Sinopharm use inactivated coronaviruses to make their vaccines — a tried-and-true method dating back over 130 years. The companies use chemicals to disable the virus’s genes so that it cannot replicate. Yet the inactivated coronavirus can still cause the body’s immune system to produce antibodies against it. By comparison, Moderna and Pfizer are taking a revolutionary gene-based approach that had never before been approved for widespread use.

Experts say there are drawbacks to inactivated vaccines like the ones being made by Sinovac and Sinopharm. They require starting off with large batches of live coronavirus samples, which can pose a biosecurity risk. Once the live samples are inactivated, it takes an extra manufacturing step to ensure that none of them survive the treatment.

Another advantage of the vaccines produced by Moderna and Pfizer is that they are faster to make and said to be more stable than traditional vaccines. Pfizer projects that it will be able to produce up to 1.3 billion doses in 2021, while Moderna expects to be able to make 500 million to one billion doses.

The Chinese government has promised to produce 610 million doses by the end of the year and expects to make more than one billion doses next year. Several large countries like Brazil and Indonesia, where Chinese companies have been conducting trials, have each received shipments of more than a million doses of Sinovac vaccines. Turkey has ordered 50 million doses.

People who were previously vaccinated in China have said the two-dose regimen costs about $60 to $150. According to people who have received the Sinovac vaccine, the company is charging about $30 a dose. Sinopharm has said the cost of two doses should be lower than $150. Zeng Yixin, the deputy minister of the National Health Commission, said on Thursday that the vaccine would be provided to the Chinese public for free, a reversal of previous statements by Chinese officials.

Reporting and research were contributed byElsie Chen, Claire Fuand Amber Wang.